PF-07202954

PF-07202954 is a small molecule, orally administered inhibitor of diacylglycerol O-acyltransferase 2 (DGAT2), developed by Pfizer. It was designed to reduce hepatic triglyceride content and fibrosis, particularly in advanced liver diseases such as non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatotic liver disease. The drug exhibits a weakly basic profile with optimized potency, clearance, and permeability due to strategic modifications including the addition of fluorine atoms. Preclinical studies demonstrated that PF-07202954 lowers liver triglyceride levels in animal models fed high-fat diets. Clinical development reached Phase 1 trials for several liver-related indications but has since been discontinued[1][2][3][4][5][6][7].